SynthesisFrontiers in immunology2022
Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Repeated faecal microbiota transplantation for individuals with type 1 diabetes and gastroenteropathy.Diabetologia · 2025Trial
- Trial
- From genes to environment: A life-course approach to prevent pediatric autoimmune diseases.World journal of clinical pediatrics · 2026Review
- Is a Functional Cure Possible in Autoimmune Diseases? Evidence from Trigger Eradication, Transplantation, and Cellular Therapies.Rheumatology and therapy · 2026Review
- Washed microbiota transplantation relieves atopic dermatitis via gut-skin microbiome rebalancing.BMC microbiology · 2026Article
- Microbiota and mycobiota in chronic inflammatory demyelinating polyneuropathy: clinical and pathophysiological correlations.Frontiers in molecular neuroscience · 2026Article
- Frontier research and clinical application prospects of microbiome biomarkers in autoimmune diseases.Frontiers in immunology · 2026Review
- An overview of the role of the gut microbiota in rheumatoid arthritis.Microbiome research reports · 2026Review
- Host-gut microbiota interactions in health and disease: mechanisms and intervention strategies.Frontiers in microbiology · 2026Review
- Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets.Frontiers in immunology · 2026Review
- Article
- Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- The Role of Gut Microbiota in Modulating Immune Signaling Pathways in Autoimmune Diseases.Neuromolecular medicine · 2025Review
- Possible Applications of Fecal Microbiota Transplantation in the Pediatric Population: A Systematic Review.Biomedicines · 2025Review
- Exploring the immunomodulatory mechanism of total glucosides of paeony on Sjögren's syndrome dry eye disease based on the "gut-eye axis" pathway.International ophthalmology · 2025Article
- The Role of Notch Signaling and Gut Microbiota in Autoinflammatory Diseases: Mechanisms and Future Views.Biomedicines · 2025Review
- Role of Gut Microbiota in the Development of Some Autoimmune Diseases.Journal of inflammation research · 2025Review
- Harnessing gut-derived bioactives and AI diagnostics for the next generation of type 2 diabetes solutions.Frontiers in endocrinology · 2025Review
- Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease.Frontiers in immunology · 2025Review
- Integrated analysis of fecal microbiota and metabolomics reveals unique characteristics of asymptomatic and classic celiac disease.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases. Methods: Relevant literature was retrieved from the PubMed database, Embase database, Cochrane Library database, etc. The search period is from the establishment of the database to January 2022. The outcomes include clinical symptoms, improvement in biochemistry, improvement in intestinal microbiota, improvement in the immune system, and adverse events. Literature screening and data extraction were independently carried out by two researchers according to the inclusion and exclusion criteria, and RevMan 5.3 software was used for statistics and analysis. Results: Overall, a total of 14 randomized controlled trials (RCTs) involving six types of autoimmune diseases were included. The results showed the following. 1) Type 1 diabetes mellitus (T1DM): compared with the autologous fecal microbiota transplantation (FMT) group (control group), the fasting plasma C peptide in the allogenic FMT group at 12 months was lower. 2) Systemic sclerosis: at week 4, compared with one of two placebo controls, three patients in the experimental group reported a major improvement in fecal incontinence. 3) Ulcerative colitis, pediatric ulcerative colitis, and Crohn's disease: FMT may increase clinical remission, clinical response, and endoscopic remission for patients with ulcerative colitis and increase clinical remission for patients with Crohn's disease. 4) Psoriatic arthritis: there was no difference in the ratio of ACR20 between the two groups. Conclusion: Based on current evidence, the application of FMT in the treatment of autoimmune diseases is effective and relatively safe, and it is expected to be used as a method to induce remission of active autoimmune diseases. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021235055, identifier CRD42021235055.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.